Medical Condition News

RSS

New analysis confirms canagliflozin's cardiovascular and kidney benefits in older adults

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients' age.

26 Oct 2024

Study: GLP-1RA not associated with acute kidney injury risk during anti-cancer treatments

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear.

26 Oct 2024

Global analysis reveals tripling of chronic kidney disease cases in women

A recent analysis reveals that the number of chronic kidney disease (CKD) cases in women around the globe nearly tripled in the past three decades.

26 Oct 2024

Wayne State University researcher secures $2.3 million for Alzheimer's studies

A Wayne State University School of Medicine faculty member has been awarded a total of $2.3 million by the National Institute on Aging of the National institutes of Health for two new, concurrent projects that both address questions related to Alzheimer's disease, a progressive, age-related degenerative brain disease characterized by memory problems, impaired judgment, cognitive issues and changes in personality.

26 Oct 2024

The importance of muscle preservation in medically induced weight loss

A recent commentary published in The Lancet journal highlights the critical importance of skeletal muscle mass in the context of medically induced weight loss, particularly with the widespread use of GLP-1 receptor agonists.

26 Oct 2024

MMRI professor receives $3.7 million NIH grant to support research on pulmonary embolism

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) recently awarded a $3.7 million grant to support a project led by Principal Investigator, Chase Kessinger, Ph.D., assistant professor of biomedical research and translational medicine at Masonic Medical Research Institute (MMRI) to research the third most common cause of cardiovascular death, pulmonary embolism (PE).

26 Oct 2024

Long-term PM2.5 exposure increases asthma risk

Asthma is currently an incurable disease that severely impairs quality of life, with recurring symptoms such as wheezing, coughing, and shortness of breath.

26 Oct 2024

Diabetes drug semaglutide proves beneficial for patients with chronic kidney damage and obesity

The diabetes drug semaglutide, also known as Ozempic, has a positive effect for patients with chronic kidney damage and obesity. They

26 Oct 2024

Study sheds new light on p53 tumor suppressor gene's role in ulcerative colitis

Researchers in the lab of Michael Sigal at the Max Delbrück Center and Charité – Universitätsmedizin Berlin have elucidated the role of the p53 gene in ulcerative colitis.

26 Oct 2024

Aerobic exercise boosts cognitive function in women undergoing chemotherapy

Many women who receive chemotherapy experience a decreased ability to remember, concentrate, and/or think—commonly referred to as “chemo-brain” or “brain fog”—both short- and long-term. In a recent clinical trial of women initiating chemotherapy for breast cancer, those who simultaneously started an aerobic exercise program self-reported greater improvements in cognitive function and quality of life compared with those receiving standard care. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

26 Oct 2024

Ipsen's elafibranor recommended for use in patients with rare liver disease

Ipsen announced today that the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. This makes elafibranor the first medicine for PBC approved for use on the NHS in nearly a decade.

26 Oct 2024

MHRA greenlights donanemab for early stage Alzheimer’s disease

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the medicine donanemab (Kisunla) for use in the early stages of Alzheimer’s disease, following a thorough review of the benefits and risks.

26 Oct 2024

Pioneering trial to test multiple new treatments for glioblastoma

A pioneering research study announced today (October 23) will trial multiple new treatments for people in the UK living with glioblastoma, an aggressive form of brain cancer.

26 Oct 2024

New research trial aims to address a disabling post-stroke condition

A major new research trial led by academics at the University of East Anglia (UEA) and taking place at eight major stroke centres across England, will test the efficacy of a new therapy for a disabling post-stroke condition that affects around one in three survivors, thanks to a £1.26m grant from the Efficacy and Mechanism Evaluation (EME) Programme - a partnership between the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC).

26 Oct 2024

Patient Claim Line outlines key signs of stroke and how to reduce risks

Every five minutes, someone in the UK will experience a stroke, with 1.3 million people in the country having survived a stroke. The condition can be both life-threatening and life-altering, so knowing what to look out for and how to act in the event of a stroke is essential.

26 Oct 2024

Surge in GLP-1 drug use for obesity coincides with drop in bariatric surgery

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter.

26 Oct 2024

Study links masculine norms to poor cardiovascular health awareness

Cardiovascular disease remains a top cause of sickness and death in the U.S. and worldwide. Doctors and researchers have it especially high on their radar because it's more modifiable and preventable than many other diseases and causes of death.

26 Oct 2024

New lung cancer screening initiative targets disparities in Central Texas

A new lung cancer screening initiative has made significant strides in overcoming barriers to care for low-income, uninsured and minority populations in Central Texas - a critical step toward reducing disparities in lung cancer outcomes.

26 Oct 2024

Taurine supplementation linked to reduced atherosclerotic plaque development

Previous studies suggest that taurine supplementation may attenuate atherosclerosis by reducing lipid levels. However, energy drinks containing taurine have been shown to increase blood pressure, a key risk factor for atherosclerosis. Thus, the role of taurine in atherosclerosis remains controversial.

26 Oct 2024

Discovery of stem-like CD4 T cells offers new hope for cancer immunotherapy

Researchers at Winship Cancer Institute of Emory University have identified a novel type of immune cell, called the stem-like CD4 T cell, that plays a pivotal role in anti-tumor immunity.

26 Oct 2024